my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
16-06-2008: AmVac AG is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the first time in tobacco plants which along with AmVac AG's adjuvant MALP-2 are to be developed into an efficient new generation of flu vaccines. The research unit for the preclinical work is being opened at the Parco Scientifico e Tecnologico in Catania, Sicily.
By switching the production base to plants, the magICON technology patented by Icon Genetics enables shorter expression times compared with current methods. As there is no contamination by animal proteins such as egg protein, the safety profile for producing antigens in tobacco plants is outstanding and has no allergy risks. It also has the potential to reduce production costs thanks to the high yields obtained in cultivating antigens. By using the innovative and high-potential adjuvant MALP-2, AmVac AG can make a decisive contribution to developing a new influenza vaccine. The immune system is stimulated, thus significantly increasing the efficacy of a vaccination. At the same time, it should be possible to reduce the amount of the antigen used and, therefore, to produce large quantities of vaccine more quickly and cost-efficiently.
Melinda-Kinga Karpati, CEO of AmVac AG, explains, "We anticipate that this collaboration with Bayer's Icon Genetics will bring us rapid results for the joint project and for our Malp-2 adjuvant. We are carrying out the work in Catania because here we have both good scientists and a high level of political support for our research. Here in Catania, we have found ideal conditions for our project with AmVac. Our goal is to achieve preclinical results with our highly motivated team locally as soon as possible and to prepare effectively for any clinical trials."
Watchlist
This is where you can add this news to your personal favourites
Kentucky Bioprocessing, LLC (KBP), Icon Genetics, GmbH (ICON) and Mapp Biopharmaceutical, Inc. (Mappbio) have announced that they have entered into detailed negotiations aimed at merging the companies to create a single, fully integrated biopharmaceutical discovery, development and manufac ... more
Medicinal products from plants or even tobacco for health - a vision that could soon become reality. Bayer and its subsidiary Icon Genetics have together developed a new production process that can be used to produce biotech drugs in tobacco plants. A new production facility for therapeutic ... more
AmVac AG Begins Research Cooperation with Bayer
AmVac AG is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for ... more
Bayer to acquire Conceptus, Inc.
Bayer intends to broaden its portfolio in the field of contraception. Thus, Bayer HealthCare LLC has signed a merger agreement with Conceptus, Inc. (CPTS), the California, U.S., based developer of the Essure® procedure, the leading non-surgical permanent birth control method, which is sold ... more
New products create optimism for the future
2012 was a very successful year for the Bayer Group. “We continued to grow dynamically and achieved our targets for the Group. All the subgroups posted gains in sales and earnings before special items,” said Bayer CEO Dr. Marijn Dekkers at the Financial News Conference in Leverkusen on Thur ... more
Humboldt Foundation cooperates with Bayer Foundation
The Alexander von Humboldt Foundation and the Bayer Science & Education Foundation will soon be awarding joint research fellowships. Until 2018, the Bayer Foundation will be making around three million EUR available to fund approximately ten Humboldt-Bayer Research Fellowships annually. The ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Pharmaceuticals Corporation
Outstanding specialty care takes constant innovation and dedication. These core values set Bayer HealthCare Pharmaceuticals apart and enable us to offer an industry-leading portfolio of products and support that healthcare providers and their patients require. Bayer HealthCare Pharmaceutic ... more
Bayer Schering GmbH, Leverkusen (formerly Dritte BV GmbH) today informed the Management Board of Schering AG that the cash compensation for the requested transfer of the shares of Schering’s minority shareholders (squeeze-out) has been determined as EUR 98.98 per Schering share. The amount ... more
Partnering with community leaders and providing philanthropic support have long been a part of Bayer Corporation's culture. In 1953, Bayer created the first of three foundations that later all merged to become the Bayer Foundation. The Bayer Foundation is an endowed 501(c)(3) entity and is ... more
AmVac AG Granted a European Patent for ProstaVac
European patent EP 1272216B1 with the title "Vaccine consisting of lactobacilli for the treatment of inflammation of the prostate and benign prostatic hyperplasia" was granted by the European Patent Office on9.6.2010. AmVac AG holds a licence for the above patent. Granting of the patent is ... more
AmVac AG Granted Patent for new Vaccine Development
AmVac AG has been granted a European patent (EP 1851 239 B1) for its Sendai platform technology for its subsidiary company AmVac Research GmbH. Thus, the novel technology for producing vaccines that has been developed at the research site in Martinsried, Germany, is completely covered by th ... more
AmVac AG Begins Research Cooperation with Bayer
AmVac AG is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
